We provide accurate and convenient detection products and technical solutions for CAR T-Cell development, quality control and clinical monitoring.
Our product have the highest sensitivity for CAR T-Cell detection in the market.
More accurate! more precise! more sensitive!
Our clients range from leading multinational companies to small startups among 5 different countries.
With our products and services, our clients have successfully accomplished many projects in CAR T-Cell therapy field.
We have established robust supply chain.
https://onlinelibrary.wiley.com/doi/full/10.1002/cyto.a.24676
Immune checkpoint inhibitor was undoubtedly a breakthrough in cancer therapy. Since FDA approved Pembrolizumab and Nivolumab for melanoma in 2014, PD-1/PD-L1 blockade has been proven to be effective in multiple cancers including lung, head and neck, kidney, breast, bladder cancer, and lymphoma.